Frontiers | Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile | Microbiology
RCSB PDB - 4NP4: Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing antibody bezlotoxumab
Therapeutic Antibodies to Track in 2017, Part I
Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography - Journal of Biological Chemistry
Mapping the binding sites for CSPG4, FZDs, and bezlotoxumab in TcdB... | Download Scientific Diagram
PDB 4np4 structure summary ‹ Protein Data Bank in Europe (PDBe) ‹ EMBL-EBI
Clostridium difficile toxin B - Wikipedia
Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab | Infection and Immunity
Frontiers | Clostridium difficile – From Colonization to Infection | Microbiology
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection | NEJM
Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection - Clinical Trials Arena
JCI Insight - Human C. difficile toxin–specific memory B cell repertoires encode poorly neutralizing antibodies
Bezlotoxumab for the prevention of Clostridium difficile inf | IDR
Update of treatment algorithms for Clostridium difficile infection - Clinical Microbiology and Infection
Zinplava (bezlotoxumab) dosing, indications, interactions, adverse effects, and more
Immune response against Clostridioides difficile and translation to therapy - Kanika Sehgal, Sahil Khanna, 2021
Bezlotoxumab: an emerging monoclonal antibody therapy for prevention o | BTT
Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota | Nature Communications
Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography - ScienceDirect
Actoxumab/Bezlotoxumab
Mechanism of Action for ZINPLAVA™ (bezlotoxumab)
Nonantimicrobial drug targets for Clostridium difficile infections | Future Microbiology
